A Phase 3 interventional study of Chemotherapy and Quizartinib in Acute Myeloid Leukemia and Leukemia, sponsored by Daiichi Sankyo. Completed at 244 sites in 28 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 3rd largest by enrollment, is one of 4 that started in 2016, is one of 5 in phase 3, and was the 8th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
Kura Oncology, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 539 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2016, is one of 3 in phase 3, and was the 10th registered.
Daiichi Sankyo’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 21 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.
Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).
Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.
This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as continuation therapy for up to 36 cycles) on overall survival in subjects with FLT3-internal tandem duplication (ITD) positive AML.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate renal function defined as:
a. >50 mL/min, as calculated with the modified Cockcroft Gault equation
Adequate hepatic function defined as:
Exclusion Criteria:
Prior treatment for AML, except for the following allowances:
Uncontrolled or significant cardiovascular disease, including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant Continuation: up to 36 cycles with the experimental drug quizartinib
Drug: Chemotherapy · Drug: Quizartinib
Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant Continuation: up to 36 cycles with placebo
Drug: Chemotherapy · Drug: Placebo
Also known as: Cytarabine, Daunorubicin, Idarubicin
Also known as: Test Product
Also known as: Placebo Control
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Overall survival is defined as the time from randomization until death from any cause.
Time frame: Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment
Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \[TF\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \>1000 neutrophils, \>100,000 platelets, \<5% blasts, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.
Time frame: Date of randomization to the date of refractory disease, relapse, or death, up to approximately 3 years after enrollment
Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Complete remission (CR) rate is defined as the percentage of participants achieving CR, defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], after induction
Time frame: Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Composite complete remission (CRc) rate is defined as the percentage of participants whose best response is complete remission (CR), defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi) at the end of first Induction cycle.
Time frame: Approximately Cycle 1 Day 21 (Induction) to end of Induction, up to approximately 120 days (each Induction cycle is up to 60 days)
Number of Participants With Treatment-emergent Adverse Events Occurring in ≥10% Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
A treatment-emergent adverse event (TEAE) is defined as an adverse event that occur, having been absent before first dose of quizartinib or placebo, or have worsened in severity after initiating quizartinib or placebo. Adverse events collected more than 30 days after the last dose of quizartinib/placebo will not be considered TEAEs unless they are considered drug-related.
Time frame: Date of first dose up to 30 days after last dose, up to 36 cycles following continuation (approximately 6 years 11 months, each cycle is 28 days)
Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Complete remission (CR) is defined as participants achieving CR defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.
Time frame: Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Composite complete remission (CRc) is defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi). Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.
Time frame: Approximately Cycle 1 Day 21 (Induction phase) to end of Induction phase, up to approximately 120 days (each Induction cycle is up to 60 days)
Pharmacokinetic Parameter Area Under the Concentration Versus Time Curve at Steady State
AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.
Time frame: Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Pharmacokinetic Parameter Steady State, Maximum Plasma Concentration (Css,Max)
Css,max was assessed by population PK analysis during Cycle 1 of each phase.
Time frame: Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
Pharmacokinetic Parameter Time to Maximum Plasma Concentration Steady State (Tmax,ss)
Tmax,ss was assessed by population PK analysis during Cycle 1 of each phase.
Time frame: Induction Cycle 1: Day 8, predose, 2-4 hours (hr) postdose on Days 8, 15, 21; Consolidation Cycle 1: Day 6, predose, 2-4 hr postdose on Days 6, 13, 19; Continuation Cycle 1: 2-4 hr postdose, Days 1, 8, 15; Cycle 2 Days 1 and 15 (each cycle, 28 days)
A total of 539 participants who met all inclusion criteria and no exclusion criteria were randomized to treatment at 193 study sites in the following countries: Spain, Italy, Republic of Korea, Japan, China, US, France, Brazil, Germany, Russian Federation, Taiwan, Hungary, Czech Republic, Romania, Israel, Canada, Serbia, Poland, Portugal, Australia, Belgium, Bulgaria, Croatia, Ukraine, Singapore, and the UK. A total of 6 participants were randomized, but did not received treatment.
| Milestone | Quizartinib | Placebo |
|---|---|---|
| Started | 268 | 271 |
| Safety analysis set | 265 | 268 |
| Completed | 56 | 52 |
| Not completed | 212 | 219 |
| Withdrew: Refractory disease | 41 | 70 |
| Withdrew: Relapse | 44 | 65 |
| Withdrew: Adverse event | 58 | 23 |
| Withdrew: Subject decision to stop study drug | 25 | 23 |
| Withdrew: Other reasons not specified | 16 | 11 |
| Withdrew: Non-protocol-specified aml therapy | 12 | 6 |
| Withdrew: Investigator decision | 10 | 7 |
| Withdrew: Failure to meet continuation criteria | 5 | 12 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Death | 0 | 1 |
Overall survival is defined as the time from randomization until death from any cause.
| months | Quizartinib | Placebo |
|---|---|---|
| Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 31.9 (21.0 to NA) | 15.1 (13.2 to 26.2) |
Event-free survival (EFS) is the time from randomization to the earliest date of either refractory disease (or treatment failure \[TF\]), relapse, or death from any cause. Refractory disease is defined as complete remission never achieved during Induction (CR: \>1000 neutrophils, \>100,000 platelets, \<5% blasts, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]). For refractory disease, EFS event date is Day 1 (randomization). Relapse after CR is defined as ≥5% blasts, leukemic blasts, extramedullary leukemia, and presence of rods. This analysis is based on a response assessment with TF defined as not achieving response of CR, using a 42- day window from the start of the last cycle in Induction for CR evaluation.
| months | Quizartinib | Placebo |
|---|---|---|
| Event-free Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 0.03 (0.03 to 0.95) | 0.71 (0.03 to 3.42) |
Complete remission (CR) rate is defined as the percentage of participants achieving CR, defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], after induction
| Participants | Quizartinib | Placebo |
|---|---|---|
| Complete Remission (CR) Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 147 | 150 |
Composite complete remission (CRc) rate is defined as the percentage of participants whose best response is complete remission (CR), defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi) at the end of first Induction cycle.
| Participants | Quizartinib | Placebo |
|---|---|---|
| Composite CR Rate at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 192 | 176 |
A treatment-emergent adverse event (TEAE) is defined as an adverse event that occur, having been absent before first dose of quizartinib or placebo, or have worsened in severity after initiating quizartinib or placebo. Adverse events collected more than 30 days after the last dose of quizartinib/placebo will not be considered TEAEs unless they are considered drug-related.
| Participants | Quizartinib | Placebo |
|---|---|---|
| Any TEAE | 264 | 265 |
| Gastrointestinal disorders | 215 | 209 |
| Diarrhoea | 98 | 94 |
| Nausea | 90 | 84 |
| Vomiting | 65 | 53 |
| Stomatitis | 57 | 56 |
| Constipation | 56 | 69 |
| Abdominal pain | 46 | 38 |
| Dyspepsia | 30 | 23 |
| Abdominal pain upper | 29 | 25 |
| Infections and infestations | 204 | 188 |
| Pneumonia | 39 | 41 |
| Sepsis | 15 | 28 |
| General disorders and administration site disorders | 177 | 173 |
| Pyrexia | 112 | 109 |
| Oedema peripheral | 30 | 37 |
| Fatigue | 29 | 23 |
| Blood and lymphatic system disorders | 168 | 143 |
| Febrile neutropenia | 117 | 113 |
| Neutropenia | 54 | 27 |
| Thrombocytopenia | 30 | 30 |
| Anaemia | 29 | 19 |
| Metabolism and nutrition disorders | 165 | 153 |
| Hypokalaemia | 93 | 96 |
| Decreased appetite | 46 | 36 |
| Hypomagnesaemia | 30 | 30 |
| Hypophosphataemia | 27 | 24 |
| Hypocalcaemia | 26 | 29 |
| Skin and subcutaneous tissue disorders | 152 | 158 |
| Rash | 69 | 66 |
| Pruritus | 35 | 40 |
| Investigations | 140 | 105 |
| Alanine aminotransferase increased | 42 | 27 |
| Electrocardiogram QT prolonged | 36 | 11 |
| Aspartate aminotransferase increased | 28 | 19 |
| Neutrophil count decreased | 27 | 12 |
| Respiratory, thoracic, and mediastinal disorders | 123 | 115 |
| Cough | 50 | 44 |
| Epistaxis | 40 | 29 |
| Oropharyngeal pain | 27 | 18 |
| Nervous system disorders | 103 | 97 |
| Headache | 73 | 53 |
| Musculoskeletal and connective tissue disorders | 91 | 108 |
| Arthralgia | 29 | 35 |
| Back pain | 19 | 28 |
| Vascular disorders | 71 | 70 |
| Hypertension | 29 | 33 |
| Psychiatric disorders | 57 | 50 |
| Insomnia | 37 | 30 |
Complete remission (CR) is defined as participants achieving CR defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\]. Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.
| Participants | Quizartinib | Placebo |
|---|---|---|
| Number of Participants Achieving CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 54 | 51 |
Composite complete remission (CRc) is defined as \<5% blasts, \>1000 neutrophils, \>100,000 platelets, and other \[defined as absence of extramedullary disease \[EMD\], blasts with rods, and leukemic blasts\], or CR with incomplete neutrophil or platelet recovery (CRi). Minimal or measurable residual disease is the presence of a small number of leukemic cells in the bone marrow of patients with AML below the level of detection using conventional morphologic assessment.
| Participants | Quizartinib | Placebo |
|---|---|---|
| Number of Participants Achieving Composite CR With FLT3-ITD Minimal Residual Disease Negativity at the End of Induction in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia | 66 | 58 |
AUCss was assessed by population Pharmacokinetic (PK) analysis during Cycle 1 of each phase.
| nanogram/milliliter (ng/mL) | Quizartinib |
|---|---|
| Induction Period | 2680 ± 84.9 |
| Consolidation Period | 3930 ± 77.6 |
| Continuation Period - Dose 1 | 5080 ± 74.7 |
| Continuation Period - Dose 2 | 10200 ± 74.7 |
Css,max was assessed by population PK analysis during Cycle 1 of each phase.
| nanogram/milliliter (ng/mL) | Quizartinib |
|---|---|
| Induction Period | 140 ± 71.2 |
| Consolidation Period | 204 ± 63.5 |
| Continuation Period - Dose 1 | 265 ± 59.7 |
| Continuation Period - Dose 2 | 529 ± 59.7 |
Tmax,ss was assessed by population PK analysis during Cycle 1 of each phase.
| hours | Quizartinib |
|---|---|
| Induction Period | 2.68 (1.52 to 7.30) |
| Consolidation Period | 2.70 (1.74 to 5.95) |
| Continuation Period - Dose 1 | 2.73 (1.74 to 5.95) |
| Continuation Period - Dose 2 | 2.73 (1.74 to 5.95) |
Collected over Treatment-emergent adverse events were collected from date of first dose up to 30 days after last dose, up to 36 cycles following continuation phase (approximately 6 years 11 months, each cycle is 28 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quizartinib | 130/265 (49.1%) | 146/265 (55.1%) | 258/265 (97.4%) |
| Placebo | 156/268 (58.2%) | 124/268 (46.3%) | 258/268 (96.3%) |
| Event | Quizartinib | Placebo |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 29/265 | 22/268 |
| PneumoniaInfections and infestations | 17/265 | 15/268 |
| SepsisInfections and infestations | 10/265 | 14/268 |
| Septic shockInfections and infestations | 11/265 | 9/268 |
| PyrexiaGeneral disorders | 8/265 | 5/268 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/265 | 8/268 |
| Klebsiella sepsisInfections and infestations | 7/265 | 1/268 |
| Herpes zosterInfections and infestations | 5/265 | 1/268 |
| NeutropeniaBlood and lymphatic system disorders | 4/265 | 5/268 |
| Anal fistulaGastrointestinal disorders | 4/265 | 0/268 |
| Event | Quizartinib | Placebo |
|---|---|---|
| PyrexiaGeneral disorders | 113/265 | 106/268 |
| Febrile neutropeniaBlood and lymphatic system disorders | 98/265 | 97/268 |
| DiarrhoeaGastrointestinal disorders | 97/265 | 94/268 |
| HypokalaemiaMetabolism and nutrition disorders | 93/265 | 96/268 |
| NauseaGastrointestinal disorders | 91/265 | 84/268 |
| HeadacheNervous system disorders | 73/265 | 54/268 |
| RashSkin and subcutaneous tissue disorders | 69/265 | 66/268 |
| ConstipationGastrointestinal disorders | 57/265 | 69/268 |
| VomitingGastrointestinal disorders | 63/265 | 51/268 |
| StomatitisGastrointestinal disorders | 56/265 | 55/268 |
Demographic and baseline characteristics were assessed in the Intent-to-Treat Analysis Set.
| Age, Continuous(years) | Quizartinib | Placebo | Total |
|---|---|---|---|
| Mean | 53.6 ± 13.07 | 54.3 ± 12.81 | 54.0 ± 12.93 |
| Age, Customized(Participants) | Quizartinib | Placebo | Total |
|---|---|---|---|
| <60 years | 161 | 162 | 323 |
| ≥60 years | 107 | 109 | 216 |
| Sex: Female, Male(Participants) | Quizartinib | Placebo | Total |
|---|---|---|---|
| Female | 144 | 150 | 294 |
| Male | 124 | 121 | 245 |
| Race/Ethnicity, Customized(Participants) | Quizartinib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 80 | 78 | 158 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 5 | 7 |
| White | 159 | 163 | 322 |
| Other | 27 | 24 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Quizartinib | Placebo | Total |
|---|---|---|---|
| Singapore | 6 | 2 | 8 |
| United States | 8 | 13 | 21 |
| Czechia | 17 | 15 | 32 |
| Portugal | 3 | 6 | 9 |
| Russia | 13 | 6 | 19 |
| South Korea | 36 | 34 | 70 |
| China | 9 | 11 | 20 |
| Brazil | 7 | 8 | 15 |
| Poland | 3 | 8 | 11 |
| Bulgaria | 1 | 1 | 2 |
| France | 13 | 12 | 25 |
| Serbia | 12 | 6 | 18 |
| Croatia | 5 | 10 | 15 |
| Romania | 6 | 11 | 17 |
| Hungary | 4 | 5 | 9 |
| Japan | 16 | 13 | 29 |
| Ukraine | 2 | 1 | 3 |
| United Kingdom | 1 | 0 | 1 |
| Spain | 33 | 34 | 67 |
| Canada | 8 | 5 | 13 |
| Belgium | 4 | 3 | 7 |
| Taiwan | 12 | 17 | 29 |
| Italy | 31 | 29 | 60 |
| Israel | 5 | 9 | 14 |
| Australia | 3 | 5 | 8 |
| Germany | 10 | 7 | 17 |
Showing the first 100 of 244 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
Ran from Sep 2016 to primary completion in Aug 2021, 59 months.
Results were first posted in Oct 2022, 1 year 1 month after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 59 months is above that.
Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quizartinib